Ovid Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Ovid Therapeutics

11/03/2025 12:32

Ovid Therapeutics Inc OVID.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -22 cents.  The mean expectation of eight analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -19 cents to -15 cents per share.

Revenue fell 46.5% to $76.00 thousand from a year ago; analysts expected $189.29 thousand.

Ovid Therapeutics Inc's reported EPS for the quarter was a loss of 13 cents​.

The company reported a quarterly loss of $9.28 million.

Ovid Therapeutics Inc shares had fallen by 47.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ovid Therapeutics Inc is $3.50

This summary was machine generated from LSEG data March 11 at 12:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.17
-0.13
Beat
Sep. 30 2024
-0.20
-0.20
Met
Jun. 30 2024
-0.22
0.12
Beat
Mar. 31 2024
-0.22
-0.17
Beat